

The national board of Science for Life Laboratory

Minutes from board meeting no 32 2018-10-22 (per capsulam)

Present members: Carl-Henrik Heldin (chair), Karin Dahlman-Wright (KI), Fredrik Elinder (LiU), Sophia Hober (KTH), Anders Karlhede (SU), Margareta Olsson Birgersson (industry representative), Stellan Sandler (UU), Marianne Sommarin (UmU), Gunilla Westergren-Thorsson (LU).

Infrastructure budget 2019 and 2020

At the SciLifeLab board meeting 2018-10-04 the board was informed about the preliminary budget 2019 and 2020 for the infrastructure. The board was in favor of the budget proposal but postponed the budget decision until all details were set. All details of the infrastructure budget have now been presented to the board (see appendices).

Decision:

- The SciLifeLab board approved the budget for the national infrastructure and for Drug discovery and Development (DDD) according to the appendices. The DDD management is asked to suggest a distribution (among facilities within DDD) of the funding to the SciLifeLab management before November 6, 2018. This distribution must be approved by the board.

Anna Höglund Rehn, secretary	 	
Minutes approved by:		
Carl-Henrik Heldin		

National infrastructure budget 2019-2020

Appendix to SciLifeLab board decision per capsulam 2018-10-22

Platform	Facility / Facility Node	Current SciLifeLab funding (kSEK)	Proposed funding (kSEK)		
		2018	2019	2020	
		Compute and Storage	2 800	3 400	3 400
Bioinformatics	Disinformation	Long-term Support	4 800	4 800	4 800
Diolitionnatics		Support and Infrastructure	6 500	6 500	6 500
		Systems Biology	4 000	4 000	4 000
		Advanced Light Microscopy	3 400	3 400	3 400
		BioImage Informatics	2 500	2 800	2 800
		Cell Profiling	3 000	3 000	3 000
Cellular and Molecul	ar Imaging	Cryo-EM Stockholm	4 500	4 500	4 500
		Cryo-EM Umeå	4 000	4 000	4 000
		Protein Science Facility	1 920	1 728	1 536
		Swedish NMR Centre	3 000	3 000	3 000
		Chemical Biology Consortium Sweden Stockholm	3 150	3 150	3 150
Chemical Biology an Engineering	d Genome	Chemical Biology Consortium Sweden Umeå	1 850	1 850	1 850
		Genome Engineering Zebrafish	2 400	2 400	2 400
		High Throughput Genome Engineering	2 800 2 200	3 200	3 200
		Clinical Genomics Göteborg Clinical Genomics Lund	2 200		
Diagnostics Development	Clinical Genomics Stockholm	5 000	13 600	13 600	
			2 700	-	
Drug discovery and o	development	Clinical Genomics Uppsala DDD	1 000	1 000	1 000
		Ancient DNA	2 000	0	2 000
		Eukaryotic Single Cell Genomics	6 000	6 000	6 000
Genomics	Microbial Single Cell Genomics	2 200	2 200	2 200	
	NGI Stockholm	22 900	21 900	21 900	
	NGI Uppsala SNP&SEQ	12 900	13 900	13 900	
	NGI Uppsala UGC	8 700	8 700	8 700	
		Autoimmunity Profiling	2 400	3 000	3 000
	Chemical Proteomics and Proteogenomics (KI, MBB)	1 600	1 600	1 600	
	Chemical Proteomics and Proteogenomics (KI, OncPat)	2 400	3 000	3 000	
		Clinical Biomarkers	400	200	0
Proteomics and Meta	abolomics	Mass Cytometry Linköping	2 000	2 000	2 000
		Mass Cytometry Stockholm	4 000	4 000	4 000
	PLA Proteomics	2 800	3 800	3 800	
	Single Cell Proteomics	1 000	0	0	
	Plasma Profiling	3 200	3 200	3 200	
	Swedish Metabolomics Centre	3 000	3 600	3 600	
		SUM	141 220	143 428	145 036

Phase-out from 2019-07-01 (thereafter 80% of current funding for 18 months). Protein production within SciLifeLab beyond 2020 needs to be investigated strategically and coordinated on a national level with MaxIV and other key stakeholders.

DD is suggested to during 2019 and 2020 evaluate possibilities to form form a national facility/platform "Clinical Genomics Sweden" that covers also Linköping, Umeå and Örebro. Increased funding is dedicated to form this national platform and to boost WGS operations. The organization of the facility/platform and the conditions for funding will be defined for the November 2018 board meeting.

^{***} Launch of the facility is delayed. Suggest a break in funding in 2019 and then re-evaluation of the situation

PLA Proteomics and Single Cell proteomics to be merged from 2019–01–01 with unchanged total funding. Proposed new name of facility: PLA and Single Cell Proteomics.

Drug Discovery and Development (DDD) budget 2019-2020

Appendix to SciLifeLab board decision per capsulam 2018-10-22

Platform	Facility / Facility Node	Current SciLifeLab funding (kSEK)	Proposed funding (kSEK)	
		2018	2019	2020*
Drug discovery and development	DDD	46 154	46 514	46 514
	SUM	46 154	46 514	46 514

DDD is asked to suggest to the SciLifeLab Director and Head of operations, a internal distribution of funding for the facilities and sections within DDD. This distribution must be approved by the SciLifeLab board. The funding for 2020 is preliminary as it is depending on the funding of Operations office.